Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

More News

CAR T cell | Image credit: Maverick - stock.adobe.com
September 29th 2023

Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma

Russ Conroy
Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.
Lung cancer illustration | Image credit: Dr_Microbe - stock.adobe.com
September 20th 2023

First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC

Rose McNulty
In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Lung cancer illustration | Image credit: SciePro - stock.adobe.com
September 13th 2023

Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC

Rose McNulty
The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
Blood cells
August 24th 2023

Second-Line Axi-Cel Produces Complete Metabolic Responses in Transplant-Ineligible LBCL

Chris Ryan
Second-line treatment with axicabtagene ciloleucel (axi-cel) led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma (LBCL) who were ineligible for autologous stem cell transplant.
SAP logo | Image credit: AJMC
August 16th 2023

Verily, OneOncology Create Clinical Trial Partnership to Feature Use of SignalPath Across Practices

Mary Caffrey
Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders said in interviews.
Doctor holding in hand Immunotherapy: © Anar Mammadov - stock.adobe.com
August 7th 2023

As New Immunotherapy Resistance Definitions Take Shape, Adoption Challenges Remain

Jared Kaltwasser
Committees have worked for the past 4 years to develop uniform definitions of immunotherapy resistance, but they are not yet universally used.
How Antibody Drug Conjugates—and Chemotherapy Shortages—Are Affecting Patients With Bladder Cancer
August 4th 2023

How Antibody Drug Conjugates—and Chemotherapy Shortages—Are Affecting Patients With Bladder Cancer

Mary Caffrey
Coverage from the July 25, 2023, Institute for Value-Based Medicine® session held in partnerhship with Emory's Winship Cancer Institute.
ASCO 2023 logo
July 31st 2023

ASCO 2023: Multiple Myeloma

Mary Caffrey Silas Inman Jordyn Sava
Results included those for several bispecifics, used as monotherapy and in combination, including early results for 2 bispecifics used together.
Virus Cell T-Cell cancer cell with receptors dendritic cells antigen-presenting cells mammalian immune system virus and virology concept 3d rendering: © catalin - stock.adobe.com
July 29th 2023

Group Highlights Barriers to CAR T-Cell Referral for DLBCL

Jaime Rosenberg
The researchers emphasized the importance of early referral for chimeric antigen receptor (CAR) T-cell treatment, as patients eligible for the treatment are often in very late stages of disease, and mitigating delays in care has the potential to improve response rates by more than 10%.
Immuno-oncology
July 29th 2023

Overall Survival in Advanced NSCLC Unaffected by Immunotherapy Duration Beyond 2 Years

Kyle Munz
Researchers seeking answers regarding the most beneficial duration of immune checkpoint inhibitor–based therapy for non–small cell lung cancer (NSCLC) found no significant impact of indefinite-duration treatment on patient survival.
T cell
July 20th 2023

Research Suggests Leveraging αβ T Cell Receptor Mechanobiology Could Improve Cancer Therapy

Jared Kaltwasser
Significant mechanobiological advances have not yet been incorporated into oncology treatment, the authors wrote. 
Lungs
July 15th 2023

Pembrolizumab Sustains Efficacy at 5 Years in First-Line, PD-L1+, Advanced NSCLC

Nichole Tucker
Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer (NSCLC).
electrophoresis device in a genetics lab to decrypt the genetic code: © luchschenF - stock.adobe.com
July 12th 2023

Report Provides Recommendations on NGS Use for Metastatic Cancers in the Asia-Pacific Region

Gianna Melillo
The uptake of next-generation sequencing (NGS) in clinical practice varies across the region.
Scientific illustration of complex nanoparticles, Generative AI: © Glen - stock.adobe.com
July 6th 2023

Smart Nanoparticles Advance Use of Nucleic Acid Technology in Cancer Immunotherapy

Gwen Mergian
Recent developments in nanoparticle-mediated cancer immunotherapy promote treatment with less toxicity.
Concentrated Surgical team operating a patient in an operation theater. Well-trained anesthesiologist with years of training with complex machines follows the patient throughout the surgery: © alfa27 - stock.adobe.com
June 27th 2023

CAR T Therapy Has Comparable Efficacy in Patients With Lymphoma Who Undergo Solid Organ Transplants

Jared Kaltwasser
More data are needed to confirm the findings and assess individual risk levels, the authors said.
Review Highlights Progress, Challenges With CRS in Cancer Immunotherapies
June 24th 2023

Review Highlights Progress, Challenges With CRS in Cancer Immunotherapies

Jared Kaltwasser
A new review outlines strategies that may help reduce the risk of severe cytokine release syndrome (CRS) for patients treated with immunotherapy.
At 5 Years, Data Affirm Durability of Axi-Cel Response in Refractory LBCL
June 22nd 2023

At 5 Years, Data Affirm Durability of Axi-Cel Response in Refractory LBCL

Jared Kaltwasser
Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.
CD22 CAR T Cells Show Relatively Mild Neurotoxicity, Study Finds
June 19th 2023

CD22 CAR T Cells Show Relatively Mild Neurotoxicity, Study Finds

Jared Kaltwasser
Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.
Study Finds Axi-Cel Benefits Older Patients With Relapsed or Refractory LBCL
June 17th 2023

Study Finds Axi-Cel Benefits Older Patients With Relapsed or Refractory LBCL

Jared Kaltwasser
The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023

Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes

Rose McNulty
The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Doctor holding Blood tube for Thrombosis Risk factor test. Bleeding disorder: © Saiful52 - stock.adobe.com
June 2nd 2023

Researchers Identify Potential Risk Factors of Uncommon Thrombotic Events Following CAR T-Cell Treatment

Jaime Rosenberg
The study, wrote the researchers, offers insight into emerging and uncommon complications following chimeric antigen receptor (CAR) T-cell therapy.
Genetically engineered chimeric antigen receptor immune cell with implanted mrna gene strand - 3d illustration: Christoph Burgstedt - stock.adobe.com
May 25th 2023

Anti-CD22 CAR T Cells Show Promise in ALL, NHL

Jared Kaltwasser
Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
Sigrun Hallmeyer, MD, Advocate Health
May 17th 2023

Dr Sigrun Hallmeyer Discusses Why a Team Effort Is Vital in Precision Medicine

Maggie L. Shaw
Precision medicine starts with the patient-physician relationship, and this also involves an entire care team, emphasized Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Axicabtagene Ciloleucel, Chimeric antigen receptor (CAR) T-cell therapy for cancer: © luchschenF - stock.adobe.com
May 12th 2023

Study Examines Axi-Cel Use for Follicular Lymphoma Management

Gianna Melillo
Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel.
Kevin Davies, PhD, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
May 8th 2023

Dr Kevin Davies Discusses Progress Made With CRISPR

Maggie L. Shaw
Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?
May 6th 2023

Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?

Mary Caffrey
For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
QCCA logo
May 5th 2023

COA Surveys Practices on EOM Interest Amid Changing Times in Community Oncology

Mary Caffrey
An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023

Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs

Rose McNulty
A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Personalized mRNA Cancer Vaccine With Pembrolizumab Significantly Prolonged Recurrence Free Survival in Resected High-risk Melanoma
April 27th 2023

Personalized mRNA Cancer Vaccine With Pembrolizumab Significantly Prolonged Recurrence Free Survival in Resected High-risk Melanoma

Alana Hippensteele, MA
These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.
Shiela Plasencia, director of practice support, Community Oncology Alliance
April 18th 2023

Shiela Plasencia on the Use of Social Determinants Data Collection in Oncology Care

Pearl Steinzor
Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.
<12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo